Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech ...

A modern biomanufacturing ecosystem cannot rely on a handful of elite institutions or centralized research centers. HBCUs can ...